,address1,address2,city,state,zip,country,phone,fax,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Dr. Herriot  Tabuteau M.D.', 'age': 54, 'title': 'Founder, Chairman, CEO & Pres', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 1320968, 'exercisedValue': 0, 'unexercisedValue': 87923912}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
1,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Mr. Nick  Pizzie CPA, M.B.A.', 'age': 47, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 732941, 'exercisedValue': 0, 'unexercisedValue': 17865770}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
2,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Mr. Mark L. Jacobson', 'age': 39, 'title': 'COO & Sec.', 'yearBorn': 1983, 'fiscalYear': 2022, 'totalPay': 784661, 'exercisedValue': 0, 'unexercisedValue': 28273134}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
3,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Mr. Hunter  Murdock Esq.', 'age': 42, 'title': 'Gen. Counsel & Sec.', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 735388, 'exercisedValue': 0, 'unexercisedValue': 909595}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
4,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Dr. Amanda  Jones Pharm.D.', 'age': 39, 'title': 'Sr. VP of Clinical Devel.', 'yearBorn': 1983, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
5,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Ms. Lori  Englebert M.B.A.', 'age': 44, 'title': 'Exec. VP of Commercial & Bus. Devel.', 'yearBorn': 1978, 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
6,22 Cortlandt Street,16th Floor,New York,NY,10007,United States,212 332 3241,212 320 0245,https://www.axsome.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.",422,"{'maxAge': 1, 'name': 'Joseph  Debrah-Afful CPA, M.B.A.', 'title': 'Director of Fin.', 'exercisedValue': 0, 'unexercisedValue': 0}",9,9,8,8,9,1693526400,1672444800,86400,2,76.2,76.06,74.65,76.245,76.2,76.06,74.65,76.245,0.0,1.862033,-29.629923,1453147,1453147,867738,696920,696920,72.77,75.25,1100,1100,3551594752,38.87,91.29,19.461529,75.2928,71.8814,0.0,0.0,USD,3299189504,-1.01073,34886396,47191000,8237449,9055411,1690761600,1693440000,0.17459999,0.17135,0.70652,11.24,0.21030001,47191000,5.967,12.612703,1672444800,1703980800,1688083200,-184450656,-4.26,-2.54,-0.1,18.078,-20.681,0.26148176,0.14113986,NGM,EQUITY,AXSM,AXSM,"Axsome Therapeutics, Inc.","Axsome Therapeutics, Inc.",1447943400,America/New_York,EDT,dc312fd5-deeb-376b-9b93-11451c06c191,finmb_241907563,-14400000,75.26,180.0,84.0,116.73,108.0,1.8,buy,11,437112992,9.263,-159526384,184710000,4.388,4.52,182493104,66.251,4.234,-0.25579,-1.25475,45939511,-27443354,-111490800,4.295,0.91633004,-0.87415004,-0.88831,USD,
